HC Wainwright reaffirmed their buy rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The brokerage currently has a $27.00 target price on the technology company’s stock. A number of other brokerages have also recently issued reports on COGT. Needham & Company […]
Needham & Company LLC reaffirmed their buy rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a report published on Wednesday, Benzinga reports. The firm currently has a $22.00 price target on the technology company’s stock. Several other research firms have also weighed in on COGT. Wedbush reaffirmed an outperform rating and set […]
Wedbush reaffirmed their outperform rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a research note published on Tuesday, RTT News reports. The firm currently has a $20.00 price objective on the technology company’s stock. Several other equities research analysts also recently commented on the stock. HC Wainwright cut their target price on […]
Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totalling 4,890,000 shares, a decline of 7.2% from the June 30th total of 5,270,000 shares. Based on an average daily volume of 703,500 shares, […]
Cogent Biosciences, Inc. (NASDAQ:COGT – Get Rating) major shareholder Fairmount Funds Management Llc bought 800,000 shares of Cogent Biosciences stock in a transaction dated Friday, June 9th. The shares were bought at an average cost of $12.00 per share, with a total value of $9,600,000.00. Following the completion of the transaction, the insider now directly […]